ArticleArchives of dermatological research2025
Exploring the causal relationship between vitiligo and psoriasis: a bidirectional Mendelian randomization analysis.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Observational studies have demonstrated an association between vitiligo and psoriasis. However, to date, the causal nature of this association remains uncertain. The objective of this study was to investigate the potential bidirectional causal relationship between vitiligo and psoriasis by employing a bidirectional two-sample Mendelian randomization (MR) approach. We utilized summary statistics obtained from the genome-wide association study (GWAS) conducted in European ancestry for vitiligo (N = 44,266) and psoriasis (N = 373,338). We first performed univariate MR analysis to detect potential bidirectional causality between vitiligo and psoriasis. Then, for directions in which univariate MR confirmed a causal relationship, we further conducted multivariate MR analysis to investigate independent causal effects on the outcome considering exposure to confounders. The bidirectional two-sample MR analysis showed genetic liability to vitiligo was significantly associated with an increased risk of psoriasis (OR = 1.094, 95% CI: 1.052, 1.138), but there was no significant association between genetic liability to psoriasis and risk of vitiligo (OR = 1.176, 95% CI: 0.915, 1.511). For the vitiligo to psoriasis direction, multivariate MR adjusting for smoking, drinking, body mass index, and rheumatoid arthritis showed the presumed causality was despite attenuated (OR = 1.060, 95% CI:1.035, 1.085), and remained statistically significant. Our study suggests that vitiligo is a causal risk factor for psoriasis, but the reverse may not be true. It is emphasized by the evidence from this study that enhanced early screening for psoriasis among patients with vitiligo may help to reduce the incidence of psoriasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.